Drug discovery preclinical

Denner, P, Schmalowsky, J., and Prechtl, S. 2008. High-content analysis in preclinical drug discovery. Comb. Chem. High-Throughput Screen. 11, 216-230. 

These passive obstacles to antibiotic action complicate treatment of infectious disease in the absence of highly accurate diagnostic tools to identify the infectious pathogen. Intrinsic resistance is problematic but is predictable and easily identihed in the preclinical drug discovery stages. As a result, the spectrum of susceptible microbial species is weh known before the compound enters the clinic. 

Lindsley CW, Weaver D, Conn PJ, Mamett L. Preclinical drug discovery research and training at Vanderbilt. ACS Chem. Biol. 2007 2 17-20. 

Successful preclinical drug discovery programs frequently reach a point where there is a need to choose one or two candidates from among a whole pharmacological class of new drugs for phase I testing (Welling and Tse, 1995). There is thus a crucial need to make reliable and rapid predictions of human responses from animal data. 

OTA asked NIH and the former Alcohol, Drug Abuse and Mental Health Administration (ADAMHA), which together makeup the bulk of Federal health-related R D, to estimate all of their expenditures for preclinical drug discovery, whether or not such expenditures were made as part of one of the targeted drug development programs described above. 

Easter A, Bell ME, Damewood JR Jr, Redfem WS, Valentin JP, Winter Ml, Fonck C, Bialecki RA (2009) Approaches to seizure risk assessment in preclinical drug discovery. Drug Discov Today 14 876-884. 

---